MX2023012368A - Vacuna de virus. - Google Patents

Vacuna de virus.

Info

Publication number
MX2023012368A
MX2023012368A MX2023012368A MX2023012368A MX2023012368A MX 2023012368 A MX2023012368 A MX 2023012368A MX 2023012368 A MX2023012368 A MX 2023012368A MX 2023012368 A MX2023012368 A MX 2023012368A MX 2023012368 A MX2023012368 A MX 2023012368A
Authority
MX
Mexico
Prior art keywords
virus
infection
agents
amino acid
disclosure relates
Prior art date
Application number
MX2023012368A
Other languages
English (en)
Spanish (es)
Inventor
Ugur Sahin
Alexander Muik
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of MX2023012368A publication Critical patent/MX2023012368A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023012368A 2021-04-20 2022-04-20 Vacuna de virus. MX2023012368A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2021060273 2021-04-20
PCT/EP2022/060417 WO2022223617A1 (en) 2021-04-20 2022-04-20 Virus vaccine

Publications (1)

Publication Number Publication Date
MX2023012368A true MX2023012368A (es) 2023-11-01

Family

ID=81579467

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012368A MX2023012368A (es) 2021-04-20 2022-04-20 Vacuna de virus.

Country Status (11)

Country Link
US (1) US20240383947A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326317A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024517642A (cg-RX-API-DMAC7.html)
KR (1) KR20240009419A (cg-RX-API-DMAC7.html)
CN (1) CN117750974A (cg-RX-API-DMAC7.html)
AU (1) AU2022260466A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021654A2 (cg-RX-API-DMAC7.html)
CA (1) CA3215771A1 (cg-RX-API-DMAC7.html)
IL (1) IL307762A (cg-RX-API-DMAC7.html)
MX (1) MX2023012368A (cg-RX-API-DMAC7.html)
WO (1) WO2022223617A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN117153245B (zh) * 2023-10-18 2024-03-19 无锡市疾病预防控制中心 预测新型冠状病毒S蛋白RBD区域与hACE2受体相互作用的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
DK2046826T3 (da) 2006-07-24 2011-10-24 Biorexis Pharmaceutical Corp Exendin-fusionsproteiner
US20100113339A1 (en) 2006-09-08 2010-05-06 Ablynx N. V. Serum albumin binding proteins with long half-lives
AU2008345424A1 (en) 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
CN102076713B (zh) 2008-05-02 2015-03-25 诺华股份有限公司 改进的基于纤连蛋白的结合分子及其用途
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
WO2011051478A1 (en) 2009-10-30 2011-05-05 Domain Therapeutics Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
DK2558491T3 (en) 2010-04-13 2018-10-15 Bristol Myers Squibb Co Fibronectin-based Scaffold domain proteins that bind PCSK9
EP2758436B1 (en) 2011-09-23 2019-06-12 Universität Stuttgart Serum half-life extension using immunoglobulin binding domains
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
MA46023A (fr) * 2015-10-22 2019-07-03 Modernatx Inc Vaccin contre le virus de la grippe à large spectre

Also Published As

Publication number Publication date
IL307762A (en) 2023-12-01
KR20240009419A (ko) 2024-01-22
CN117750974A (zh) 2024-03-22
AU2022260466A9 (en) 2023-11-16
JP2024517642A (ja) 2024-04-23
US20240383947A1 (en) 2024-11-21
CA3215771A1 (en) 2022-10-27
AU2022260466A1 (en) 2023-11-02
WO2022223617A1 (en) 2022-10-27
EP4326317A1 (en) 2024-02-28
BR112023021654A2 (pt) 2023-12-26

Similar Documents

Publication Publication Date Title
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
MX2024009072A (es) Vacuna contra el coronavirus.
MX2022015132A (es) Vacunas combinadas a base de acidos nucleicos.
MX2022009688A (es) Composición y métodos de vacunas de arnm contra la nueva infección por coronavirus.
EP4226938A3 (en) Coronavirus vaccine
NZ791834A (en) Vaccines against coronavirus and methods of use
WO2023147092A3 (en) Coronavirus vaccine
DE60324678D1 (de) N t-lymphozyten und damit identifizierte hsv-antigene
NO20021479D0 (no) Immunologiske signifikante herpes simplex virus antigener og metoder for å identifisere og å bruke dem
PH12022552084A1 (en) Vaccine against african swine fever virus infection
MX2023000041A (es) Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus.
WO2022197720A3 (en) Compositions and methods for treating coronavirus infection
BR112023021654A2 (pt) Vacina contra vírus
UY40490A (es) Vacunas de combinación para prevenir y/o tratar múltiples agentes infecciosos
MX2023003377A (es) Compuesto para aumentar la eficacia de los vectores virales.
WO2003011893A3 (en) Immunologically significant herpes simplex virus antigens and methods for using same
WO2022010813A3 (en) Enhancing immune responses through targeted antigen expression
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
EP4295862A3 (en) Coronavirus vaccine
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
MX2023003784A (es) Peptido derivado de proteina de sars-cov-2 y vacuna que lo contiene.
MXPA02005506A (es) Clonacion de un gen que codifica una racemasa de aminoacido derivada de tripanosoma cruzi, y usos del mismo.
DE602007010127D1 (en) Hiv-impfstoff
WO2023023591A1 (en) Development of mosaic vaccines against foot and mouth disease virus serotype o
ZA202309368B (en) Lentiviral vector, lentiviral particle for treating hepatitis b and its preparation method and application thereof